Hypothesis

Chronic low‑grade activation of nociceptors, particularly TRPV1‑positive fibers, limits the age‑related rise in circulating coagulation factors (Factor VIII, vWF, fibrinogen) by sustaining a hepatocyte‑derived anti‑inflammatory tone. Pharmacological silencing of pain with NSAIDs or opioids removes this brake, accelerating the procoagulant state and increasing thrombotic risk.

Mechanistic Rationale

Aging drives a low‑grade inflammatory milieu that up‑regulates hepatic production of clotting factors as acute‑phase reactants [1]. TRPV1 activation on sensory neurons releases substance P and CGRP, which act on sympathetic terminals and Kupffer cells to dampen NF‑κB signaling in the liver, reducing IL‑6‑driven transcription of fibrinogen and Factor VIII [3]. When NSAIDs inhibit COX‑derived prostacyclin, they also blunt the counter‑regulatory vasodilatory tone that normally accompanies TRPV1‑mediated signaling, shifting the balance toward thromboxane‑A2 dominance and enhancing platelet activation [2]. Thus, pain is not merely a symptom but a homeostatic signal that restrains the liver’s procoagulant program.

Testable Predictions

1. In aged mice, genetic ablation of TRPV1 in sensory neurons will elevate plasma Factor VIII, vWF, and fibrinogen compared with wild‑type controls, independent of overt inflammation.
2. Chronic low‑dose capsaicin (to activate TRPV1) will attenuate the age‑related increase in coagulation markers and reduce thrombin generation in plasma.
3. Older humans regularly using high‑dose NSAIDs will show a stronger correlation between NSAID dosage and plasma Factor VIII levels than age‑matched non‑users, after adjusting for CRP.
4. Blocking substance P receptors (NK1R) will mimic the effect of TRPV1 loss on hepatic fibrinogen expression, confirming the neuropeptide intermediary.

Experimental Design

• Animal study: Use 24‑month‑old C57BL/6 mice; groups: WT, TRPV1‑KO (Nav1.8‑Cre;Trpv1^fl/fl), WT + low‑dose capsaicin diet (10 ppm), WT + NSAID (ibuprofen 30 mg/kg/day). Measure plasma Factor VIII, vWF, fibrinogen, IL‑6, thrombin‑antithrombin complexes, and tail‑bleeding time after 4 weeks. Include liver RNA‑seq to assess NF‑κB target genes.
• Human observational study: Recruit 300 adults ≥65 years from a rheumatology clinic; record NSAID type/dose, pain scores (VAS), and collect fasting plasma for Factor VIII, vWF, fibrinogen, CRP, and D‑dimer. Use multivariable regression to test interaction between NSAID exposure and pain score on coagulation markers.
• In vitro: Primary mouse hepatocytes treated with substance P (± NK1R antagonist) and LPS; quantify fibrinogen mRNA and secreted protein.

Potential Limitations

Compensatory changes in other sensory pathways could mask TRPV1 effects; NSAIDs have off‑target actions beyond COX inhibition; human pain scores may not reflect nociceptor firing intensity. Address by using selective TRPV1 pharmacology and measuring substance P levels.

Implications

If validated, the hypothesis reframes analgesic use: rather than indiscriminate pain suppression, preserving low‑level nociceptor tone could be a strategy to mitigate age‑related thrombotic risk, suggesting dosing schedules or alternative analgesics that spare TRPV1 signaling.